DE60019921D1 - Verwendung von interleukin-11 zur behandlung von hämoragischem schock - Google Patents

Verwendung von interleukin-11 zur behandlung von hämoragischem schock

Info

Publication number
DE60019921D1
DE60019921D1 DE60019921T DE60019921T DE60019921D1 DE 60019921 D1 DE60019921 D1 DE 60019921D1 DE 60019921 T DE60019921 T DE 60019921T DE 60019921 T DE60019921 T DE 60019921T DE 60019921 D1 DE60019921 D1 DE 60019921D1
Authority
DE
Germany
Prior art keywords
interleukin
treatment
shock
haemoragian
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60019921T
Other languages
English (en)
Other versions
DE60019921T2 (de
Inventor
Matthew Pollack
C Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE60019921D1 publication Critical patent/DE60019921D1/de
Application granted granted Critical
Publication of DE60019921T2 publication Critical patent/DE60019921T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60019921T 1999-06-08 2000-06-08 Verwendung von interleukin-11 zur behandlung von hämoragischem schock Expired - Fee Related DE60019921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13805499P 1999-06-08 1999-06-08
US138054P 1999-06-08
PCT/US2000/015737 WO2000074707A2 (en) 1999-06-08 2000-06-08 Use of interleukin-11 to treat hemorrhagic shock

Publications (2)

Publication Number Publication Date
DE60019921D1 true DE60019921D1 (de) 2005-06-09
DE60019921T2 DE60019921T2 (de) 2006-02-16

Family

ID=22480226

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019921T Expired - Fee Related DE60019921T2 (de) 1999-06-08 2000-06-08 Verwendung von interleukin-11 zur behandlung von hämoragischem schock

Country Status (9)

Country Link
EP (1) EP1185292B1 (de)
JP (1) JP2003501396A (de)
CN (1) CN1355707A (de)
AT (1) ATE294590T1 (de)
AU (1) AU5328800A (de)
CA (1) CA2376358A1 (de)
DE (1) DE60019921T2 (de)
MX (1) MXPA01012663A (de)
WO (1) WO2000074707A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11

Also Published As

Publication number Publication date
ATE294590T1 (de) 2005-05-15
MXPA01012663A (es) 2004-10-14
JP2003501396A (ja) 2003-01-14
EP1185292A2 (de) 2002-03-13
CA2376358A1 (en) 2000-12-14
WO2000074707A3 (en) 2001-04-19
EP1185292B1 (de) 2005-05-04
CN1355707A (zh) 2002-06-26
WO2000074707A2 (en) 2000-12-14
AU5328800A (en) 2000-12-28
DE60019921T2 (de) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE350044T1 (de) Thrombopoietinmimetika
DE60025632D1 (de) Thrombopoietin-mimetika
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
DE69526206D1 (de) Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit
ATE344031T1 (de) Thrombopoietin-mimetika
DE60139466D1 (de) Behandlung von diabetes
DE60015516D1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE275143T1 (de) Verbindungen
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
ATE267608T1 (de) Verwendung von fsh zur behandlung von infertilität
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE60012836D1 (de) Verwendung von Simethicone zur Behandlung der ulzerativen Kolitis
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ATE214923T1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee